SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential driven by developments like Caffeine AI, which allows for easy app creation. Bullish sentiment is building, with some community members drawing comparisons to previous rallies of other cryptocurrencies and anticipating a significant price increase. The discussion also highlights ICP's technology as a decentralized alternative to traditional cloud services.

COTI is a fast and light confidentiality layer on Ethereum. Powered by the breakthrough cryptographic protocol Garbled Circuits and secured by Ethereum, COTI introduces the most advanced and compliant solution for data protection on the public blockchain. Paving the way for the next wave of Web3 innovation and adoption, COTI unlocks a whole new world of use cases, including confidential transactions, Artificial Intelligence, DeFi, decentralized identification, and more.

COTI

COTI is trending as the community discusses its potential in the privacy sector and its partnerships, with some comparing it favorably to ZCash. Community members are actively speculating on future price targets and highlighting COTI's technology, emphasizing its potential for growth within the crypto space. The discussion also references AI and potential tokenized asset use cases.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin is trending as the community discusses its potential in decentralized data storage and AI infrastructure, fueled by speculation of a mega squeeze. Bullish sentiment is high, with many highlighting its utility and anticipating a continued climb. However, some investors express frustration with its historical performance.

Amentum Holdings, Inc. provides mission-critical, technology-driven services in government and commercial markets. It operates through two operating segments: Critical Mission Solutions and Cyber & Intelligence. The Critical Mission Solutions segment provides test, training, and operations services for missile defense systems, IT and engineering services to defense clients and the space sector, technological solutions, including installations, decommissioning, and environmental remediation to energy clients, and other highly technical consulting solutions. The Cyber & Intelligence segment provides advanced cyber training and data analytics for government professionals, advanced communication systems and aerial mapping technologies to national security clients, and other technical services for United States defense and intelligence clients. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings ($AMTM) is gaining attention as investors discuss its potential to land a prime contract and its position as a major government service provider. Community members are comparing $AMTM to competitors with higher valuations and speculating about factors influencing its trading behavior. Some are also highlighting potential catalysts like earnings, contract awards, and long-term growth opportunities in areas like nuclear and defense.

Casey's General Stores, Inc. engages in the provision of management and operation of convenience stores and gasoline stations. It provides self-service gasoline, a wide selection of grocery items, and an array of freshly prepared food items. The firm offers food, beverages, tobacco products, health and beauty aids, automotive products, and other non-food items. The company was founded by Donald F. Lamberti in 1968 and is headquartered in Ankeny, IA.

Casey`s General Stores, Inc.

Casey's General Stores, Inc.

Casey's General Stores is trending as investors discuss its solid financial performance and expansion plans, particularly the acquisition of Fikes Wholesale. Community members are weighing in on its long-term growth potential, comparing it to other convenience store chains, and commenting on its diverse offerings like pizza and fuel. Positive analyst ratings and raised price targets are also contributing to the increased attention.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as community members discuss its potential within the AI sector and speculate about future price targets. Some investors are accumulating, viewing NEAR as undervalued, while others cite NEAR's role in cross-chain technology, decentralized finance, and data ownership. The discussion includes speculation around partnerships and technical analysis.

Avnet, Inc. engages in the provision of distribution and sale of electronic components. It operates through the Electronic Components and Farnell segments. The Electronic Components segment markets and sells semiconductors, interconnect, passive and electromechanical devices, and integrated components. The Farnell segment focuses on the distribution of electronic components and related products to the electronic system design community utilizing multi-channel sales and marketing resources. The company was founded by Charles Avnet in 1921 and is headquartered in Phoenix, AZ.

Avnet Inc.

Avnet is trending due to mixed reactions to earnings, with the company beating estimates but offering a dim outlook. Community members are weighing the implications of the guidance, and some are looking at Avnet's strategic shifts, such as its focus on embedded solutions and cloud services, for long-term potential. Overall, investors are assessing whether the near-term headwinds outweigh the company's strategic moves and dividend increases.

Oil States International, Inc. engages in the provision of manufactured products and services used in the drilling, completion, subsea, production, and infrastructure sectors of the oil and natural gas industry, as well as in the industrial and military sectors. It operates through the following segments: Offshore Manufactured Products, Completion and Production Services, Downhole Technologies, and Corporate. The Offshore Manufactured Products segment is involved in the design, manufacture, and market of capital equipment utilized on floating production systems, subsea pipeline infrastructure, and offshore drilling rigs and vessels, along with short-cycle, and other products. The Completion and Production Services segment focuses on the provision of equipment and services that are used to establish and maintain the flow of oil and natural gas from a well throughout its life cycle. The Downhole Technologies segment refers to the provision of oil and gas perforation systems and downhole tools in support of completion, intervention, wireline, and well abandonment operations. The Corporate segment represents the corporate expenses, such as those related to corporate governance, stock-based compensation, and other infrastructure support. The company was founded in July 1995 and is headquartered in Houston, TX.

Oil States International, Inc.

Oil States International is trending due to Susquehanna updating its rating to Neutral with a target between 5.5 and 6.5. The community is discussing the company's strong performance despite challenging conditions, with some speculating about a potential rise to $8 or even a buyout. Broader conversations include energy sector rebounds and the impact of rising oil production on equipment demand.

Kadena is launching one of the world’s first true scalable blockchains ready for applications.   Kadena’s public blockchain is a braided, high-throughput Proof of Work system that runs Chainweb, a protocol that delivers security and throughput. The Kadena network will unite public applications, private blockchains, and other interoperable chains in one place, driving traffic to the high-bandwidth computer at the heart of the Kadena public chain.  Kadena enterprise software is in use today by major companies in finance, healthcare, and insurance while allowing builders with a vision to skip straight from idea to product. With the launch of Kadena’s public chain, this system will support blockchain application development, from private to public and everywhere in between.    Kadena is solving the problems of Ethereum and is delivering features today that other blockchains have only begun to include on their roadmaps, including Formal Verification, interoperability, scalability, and more.  Kadena is live and ready for immediate deployment of production blockchain applications.  The Kadena token (KDA) is a digital currency that is used to pay for computation on the Kadena public chain. Similar to ETH on Ethereum, KDA on Kadena is the token in which miners are compensated for mining blocks on the network and is the transaction fee that users pay in order to have their transactions included in a block.  Applications processing volumes of transactions on the high-throughput, scalable Kadena network will execute their smart contract code using the native Kadena token. As more applications join or interoperate with the Kadena network, the number of smart contracts executed grows, as does the utility of the Kadena token.

Kadena

Kadena is trending amid community discussions around recent delistings from exchanges and the dissolving of its foundation, leading to price volatility. Some community members express concerns about the project's future, while others remain optimistic, citing ongoing development efforts and potential for a turnaround.  Bullish investors point to Kadena's technology and potential for future gains, drawing comparisons to other successful cryptocurrencies.

Cornerstone Strategic Value Fund is a management investment company that is an investment operation. They limit the fund's investment in securities issued by other investment companies.

Cornerstone Strategic Investment Fund Inc.

Cornerstone Strategic Investment Fund, Inc.

CLM is trending as investors discuss its recent price volatility and upcoming ex-dividend date, with some expressing concerns about a potential rights offering. The community is actively monitoring NAV and premiums, strategizing around DRIP and potential market reactions. Some investors are reporting difficulties trading the stock on certain platforms.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bank of New York Mellon Corp Has $113.54 Million Stock Holdings in Biogen Inc. $BIIB

Bank of New York Mellon Corp trimmed its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 5.2% in the second quarter, according to the company in its most recent filing with the SEC. The...

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug 

Denali's Q3 loss widens year over year as expenses rise, while the FDA delays its review of the firm???s key Hunter syndrome therapy to 2026.

BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View

Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.

Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.

Biogen (BIIB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Biogen (BIIB) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Biogen Inc. (BIIB) Q3 Earnings and Revenues Top Estimates

Biogen (BIIB) delivered earnings and revenue surprises of +23.65% and +8.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for

Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

<ul class="summary-bullets"><li>Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.</li><li>Vanqua will receive $70 million upfront payments and will be eligible to receive up to $990 million in milestone payments.</li><li>Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug.&nbsp; &nbsp;</li></ul>Biogen Inc. (BIIB) on Friday announced a license agreement with Vanqua Bio granting it exclusive worldwide rights to the latter’s preclinical drug candidate targeting a range of inflammatory disorders.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biogen.com/news-releases/news-release-details/biogen-licenses-oral-c5ar1-antagonist-vanqua-bio-expand">deal</a>, Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.<h2 class="st-heading-2">Terms Of The Deal</h2>Vanqua will receive $70 million in upfront payments and be eligible to receive up to $990 million in milestone payments, in addition to tiered royalties on potential net sales, as per the agreement. Biogen will lead all future development, manufacturing, and commercialization efforts of the experimental drug.Jane Grogan, Executive Vice President and Head of Research at Biogen, said that advancing the program will enable it to deepen focus on immunological diseases.Biogen expects to file an application with the U.S. Food and Drug Administration for approval of the candidate in 2027, if results remain supportive. In preclinical studies, the program demonstrated activity as well as a safety and tolerability profile supportive of advancing it into clinical development, the company noted.Last year, Biogen also acquired privately held Human Immunology Biosciences for up to $1.8 billion to expand its immunology portfolio.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> rose 1% on Friday morning at the time of writing. On Stocktwits, retail sentiment around BIIB stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:620/59;" src="data:image/png;base64,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" width="620" height="59" alt="BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>According to Koyfin data, 16 of the 35 analysts covering Biogen rate it ‘Buy’ or higher, while 19 rate it ‘Hold’. The stock has an average price target of $172.55, representing a potential upside of about 14%.BIIB stock is down by 1% this year and by about 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-acquire-adverum-biotechnologies/cLGJ8N0R3tc">Eli Lilly To Acquire Adverum Biotechnologies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal

Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug. 

Equity

Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key

Biogen is expected to top earnings forecasts again as new products offset declining multiple sclerosis drug sales.

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

BIIB
Biogen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BIIB News

BIIBBiogen Inc